

AstraZeneca: Focus on Hematology

Following the science | Developing innovative therapies | Improving the lives of patients



Leveraging our **40+ year heritage in oncology**, we're developing innovative **blood cancer treatments** that address critical unmet medical needs across our **four scientific platforms**¹:

- Immuno-Oncology
- Tumor Drivers and Resistance
- DNA Damage Response
- Antibody-Drug Conjugates



AstraZeneca's vision is to be a scientific leader in hematology by helping transform care for the **3.1 million people living with blood cancers*** worldwide as of 2018.²

*Blood cancers including leukemia, lymphoma and myeloma.

Our Pipeline



In approximately two years, we received FDA approvals in CLL and previously treated MCL, demonstrating our **rapid development of innovative treatments** across a range of hematologic malignancies.



Our robust development program includes **more than 25 monotherapy and combination clinical trials** across multiple B-cell blood cancers.³



We have identified seven disease states as **our core areas of focus**, including AML, CLL, DLBCL, MCL, MDS, MM and WM.*

*AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; MM, multiple myeloma; WM Waldenström's macroglobulinemia.

Our Approach to Research

AstraZeneca is guided first and foremost by science. Our approach to tackling the diversity and complexity of blood cancers is to identify highly promising mechanisms in our pipeline and align them with the greatest unmet need. Our key research principles include:



Our pipeline demonstrates our rapid development – finding therapeutic mechanisms validated in solid tumors that have potential application for blood cancers.



A different approach to development – exploring novel combination therapies and multimodality approaches that could transform the treatment.



Advancing our early science portfolio – a focus on investigational agents in pre-clinical to Phase II development, including exploration of mechanisms of action such as DNA damage response and cell death.

Our Commitment to the Blood Cancer Community

Each person impacted by blood cancer, whether they are a patient, caregiver, family member or friend, is another reason our researchers work every day to advance the science in hematology. We're proud to be part of and to collaborate with the blood cancer community to help transform care and to create new treatment options for those battling blood cancers.



1. AstraZeneca. Oncology. <https://www.astrazeneca.com/our-therapy-areas/oncology.html#Ourscientificplatforms>. Accessed August 2020. 2. World Health Organization. Worldwide Cancer Fact Sheet 2018 (Incidence, Mortality and Prevalence by cancer site). <http://goo.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf>. Accessed August 2020. 3. AstraZeneca. Clinical trials appendix H1 2020 results update. July 30, 2020. <https://www.astrazeneca.com/investor-relations/results-and-presentations.html>. Accessed August 2020.